$4.44
0.00160.04%
Last update: Nov 4, 5:57 PM
Gyre Therapeutics Inc
GYRENASDAQ
Gyre Therapeutics (GYRE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Gyre Therapeutics (GYRE) last issued guidance on August 7, 2026 for fiscal year 2026. The company guided revenue in the range of $100.5M - $111M for the period.
Compared to prior guidance, Gyre Therapeutics maintained its revenue forecast from a prior range of $100.5M - $111M.
Gyre Therapeutics has issued 4 guidance updates between March 17, 2025 and August 7, 2026. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | FY '23 |
|---|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||||
| Estimate | $-0.06 | $-0.07 | $0.04 | $0.01 | — |
| Actual | $-0.12 | $-0.04 | $0.05 | $0.03 | $-1.41 |
| Surprise | -100.0% | +35.7% | +15.0% | +200.0% | — |
| Revenue | |||||
| Estimate | $26.4M | $32.1M | $35.8M | $33.2M | — |
| Actual | $29.1M | $22.5M | $37.2M | $30.6M | $113.5M |
| Surprise | +10.1% | -29.8% | +3.82% | -7.77% | — |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.12 | $-0.13 |
| Revenue | ||
| Consensus | $28.4M | $29.5M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 7, 2026 | $-0.12 | $-0.06 | -100.0 % |
| Q1 | May 7, 2026 | $-0.05 | $-0.07 | 35.7 % |
| Q4 | Mar 12, 2026 | $0.05 | $0.04 | 15.0 % |
| Q3 | Nov 7, 2025 | $0.03 | $0.01 | 200.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 7, 2026 | $29.11M | $26.44M | 10.1 % |
| Q1 | May 7, 2026 | $22.52M | $32.07M | -29.8 % |
| Q4 | Mar 12, 2026 | $37.20M | $35.83M | 3.82 % |
| Q3 | Nov 7, 2025 | $30.60M | $33.18M | -7.77 % |
